The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but rejected its use for another condition, the drugmaker said on Tuesday. The ...
Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback